Is It Time To Revisit ICON (ICLR) After Its Recent Share Price Rebound?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

If you are wondering whether ICON is attractively priced or still overpriced after a tough run, a useful starting point is to understand what today's share price is actually baking in. The stock last closed at US$118.96, with the price up 6.2% over the past week and 11.4% over the past month, even though the share price is still down 36.9% year to date and has fallen 15.2% over the past year. Recent coverage has focused on how ICON fits into longer term trends in clinical research outsourcing and the broader pharmaceutical and biotech ecosystem, with investors paying close attention to its role in large scale drug development programs. This context helps explain why the share price has shown short term strength despite multi year share price declines of 42.2% over three years and 47.3% over five years. ICON currently scores a 5 out of 6 valuation score. This sets up a closer look at how different valuation methods assess the stock today and hints at a more complete way to think about fair value that will be covered at the end of this article.

Find out why ICON's -15.2% return over the last year is lagging behind its peers.

Approach 1: ICON Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and discounting them back to today, using the idea that money available now is worth more than the same amount in the future.

For ICON, the model uses a 2 Stage Free Cash Flow to Equity approach built on cash flow projections. The latest twelve month Free Cash Flow is about $980.9 million. Analyst and extrapolated estimates suggest Free Cash Flow of $861.4 million in 2026 and $979.6 million by 2030, all in $. Beyond the first few analyst covered years, Simply Wall St extends the projections to build a ten year view.

When these projected cash flows are discounted, the DCF model points to an estimated intrinsic value of about $192.16 per share. Compared with the recent share price of $118.96, this implies ICON trades at roughly a 38.1% discount to that DCF estimate, which suggests the stock screens as undervalued on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests ICON is undervalued by 38.1%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.ICLR Discounted Cash Flow as at May 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for ICON.

Approach 2: ICON Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see how much you are paying for each dollar of earnings, which makes it a common anchor for comparing stocks within the same industry.

Story Continues

Higher growth expectations and lower perceived risk usually justify a higher P/E ratio, while slower growth or higher risk tend to support a lower, more cautious P/E range. So the question is not whether a P/E is high or low in isolation, but whether it makes sense given the company’s profile.

ICON currently trades on a P/E of 15.15x, compared with the Life Sciences industry average of about 36.40x and a peer group average of 64.52x. Simply Wall St also calculates a proprietary “Fair Ratio” for ICON of 17.25x, which reflects factors such as its earnings profile, industry, profit margins, market cap and risk characteristics.

This Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for company specific growth, risks and profitability rather than assuming all companies deserve the same multiple. On this basis, ICON’s current P/E of 15.15x sits below the 17.25x Fair Ratio, which indicates the stock appears undervalued on this metric.

Result: UNDERVALUEDNasdaqGS:ICLR P/E Ratio as at May 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your ICON Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives is a simple tool that lets you attach a clear story about ICON to your own numbers for future revenue, earnings and margins, link that story to a financial forecast and then to a fair value, and see it all side by side with the current share price.

On Simply Wall St, Narratives live in the Community page and are used by millions of investors as an accessible way to spell out why they think ICON is worth a certain amount, compare that Fair Value with the live Price to decide whether they see it as attractive or expensive, and then keep that view current as new information like news, earnings or accounting updates flows in.

For ICON, one investor might align with a more optimistic Narrative that assumes earnings reach about US$1.1b by 2028 and support a Fair Value near US$226.60. Another might align with a more cautious Narrative that assumes earnings closer to US$497.1m by 2029 and a Fair Value around US$75. Seeing these side by side helps you decide which story, and which set of assumptions, fits your own view best.

For ICON, however, we’ll make it really easy for you with previews of two leading ICON Narratives:

Start with the bullish version if you think the recent weakness has pushed the stock too far down, or use the bear case if you are more focused on accounting risks and margin pressure. Your own view may sit somewhere in between, but seeing both ends laid out clearly can help you decide what needs to be true for you to be comfortable with the current price.

🐂 ICON Bull Case

Fair value in this bullish narrative: US$135.07 per share.

Implied upside from that fair value to the latest close around US$118.96 is about 12.0%. In other words, the price would need to climb by that amount to meet this estimate.

Revenue growth assumption: 1.36% a year.

Focuses on ICON using partnerships in midsized pharma, operational standardisation and AI tools like iSubmit and SmartDraft to support revenue and margin improvement over time. Builds in analyst assumptions that earnings reach about US$666.8m by 2029, with profit margins edging up and the P/E multiple at 17.9x, alongside a shrinking share count from buybacks. Flags trial cancellations, cautious client budgets, competition in biotech and pricing pressure as key risks that could challenge those earnings and valuation assumptions.

🐻 ICON Bear Case

Fair value in this bearish narrative: US$75.00 per share.

At the latest close around US$118.96, the price sits about 58.6% above this fair value. This view therefore treats the stock as expensive relative to its assumptions.

Revenue growth assumption: 0.57% a year.

Emphasises elevated trial cancellations around 2.5% of backlog, pricing pressure and higher compliance costs as ongoing headwinds for growth and margins. Assumes earnings ease to about US$497.1m by 2029, with margins lower at 6.0% and a P/E of 13.4x, using a 9.5% discount rate to arrive at the US$75.00 fair value. Accepts that stronger RFP flow, deeper partnerships, AI driven efficiencies and active capital returns could all weaken the bearish case if they prove more powerful than the headwinds.

If you want to see how other investors frame these stories and where they place ICON's fair value, it can help to read the narratives in full and stress test which set of assumptions feels closest to your own view, before deciding how comfortable you are with the current share price.

See what the community is saying about ICON

Do you think there's more to the story for ICON? Head over to our Community to see what others are saying!NasdaqGS:ICLR 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ICLR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments